Bio-Rad Laboratories Class A
491 hedge funds and large institutions have $11.5B invested in Bio-Rad Laboratories Class A in 2020 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 177 increasing their positions, 176 reducing their positions, and 57 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
33% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 57
15% more capital invested
Capital invested by funds: $9.93B → $11.5B (+$1.52B)
3% more funds holding
Funds holding: 479 → 491 (+12)
1.14% more ownership
Funds ownership: 78.37% → 79.51% (+1.1%)
1% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 176
8% less call options, than puts
Call options by funds: $14.7M | Put options by funds: $16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$164M |
| 2 |
BlackRock
New York
|
+$154M |
| 3 |
HM
HealthCor Management
New York
|
+$79.8M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$72.4M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$66.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$183M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$102M |
| 3 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$89.1M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$48.1M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$42.2M |
BIO Hedge Fund Activity: Q4 2020 in Review
491 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2020, worth a combined $11.5B — up 15% from $9.93B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new BIO positions and 57 closed out — a net gain of 19 holders — while 177 added to existing stakes and 176 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $164M. The largest seller was GQG Partners, exiting entirely with an estimated $183M sold.
- 491 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2020, up from 479 in Q3 2020.
- Funds reported $11.5B of Bio-Rad Laboratories Class A stock for Q4 2020, up 15% quarter-over-quarter.
- 76 funds opened new Bio-Rad Laboratories Class A positions in Q4 2020 and 57 closed out, a net change of +19 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q4 2020 was Fidelity Investments, an estimated $164M added.
- The largest Bio-Rad Laboratories Class A seller in Q4 2020 was GQG Partners, an estimated $183M sold.
Based on aggregated 13F filings for Q4 2020.